National Cancer Institute; Notice of Closed Meetings, 39546-39547 [2010-16803]

Download as PDF 39546 Federal Register / Vol. 75, No. 131 / Friday, July 9, 2010 / Notices against a wide range of different H5N1 strains. The combination of peptides was able to specifically detect antiH5N1 antibodies from serum samples of H5N1 survivors at early and later times post infection while excluding antibodies generated in individuals infected with other strains of influenza virus. Also, the peptides did not react with sera from individuals vaccinated with H5N1 vaccine, in contrast to the strain-specific detection of anti-H5N1 antibodies in sera from infected individuals. Immunoassays using the H5N1 peptide combination provide highly specific, sensitive and reproducible methods for diagnosing H5N1 infection in humans and animals. Applications: Diagnostics for influenza virus specific antibodies in humans and animals. Advantages: High specificity, sensitivity, and reproducibility. Development Status: Data obtained from clinical samples can be provided upon request. Market: Influenza virus diagnostics. Inventors: Hana Golding and Surender Khurana (FDA). wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 Patent Status • U.S. Patent Application No. 12/ 664,052 filed 10 Dec 2009 (HHS Reference No. E–236–2007/3–US–03). • U.S. Provisional Patent Application No. 61/325,073 filed 16 Apr 2010 (HHS Reference No. E–093–2010/0–US–01). Licensing Status: Available for licensing. Licensing Contact: Kevin W. Chang, PhD; 301–435–5018; changke@mail.nih.gov. Bacterially Expressed Influenza Virus Recombinant HA Proteins for Vaccine and Diagnostic Applications Description of Invention: Pandemic H1N1 influenza virus is a recently emergent strain of influenza virus that the World Health Organization (WHO) estimates has killed at least 14,711 people worldwide. Avian influenza viruses are emerging health threats with pandemic potential. Due to their global health implications, there has been a massive international effort to produce protective vaccines against these influenza virus strains. Currently, influenza virus vaccines are produced in chicken eggs, a production method that is disadvantaged by lengthy vaccine production times and by inability to meet large-scale, global demands. The subject technologies are specific recombinant HA proteins from H1N1, H5N1, and other strains of influenza virus produced in bacteria. The HA proteins properly fold, form oligomers, bind fetuin, agglutinate red blood cells VerDate Mar<15>2010 15:17 Jul 08, 2010 Jkt 220001 substituted IL–15 amino acid sequences may advantageously facilitate the refolding, purification, storage, characterization, and clinical testing of IL–15. Applications: IL–15 immunotherapies. Advantages: Potential decreased immunogenicity of pharmacologically active IL–15 expressed in E. coli. Development Status: Concept Applications Development Phase. Market: Cancer immunotherapy; IL– • Vaccines for the prevention of 15 based immunotherapies. influenza infection. Inventors: David F. Nellis et al. (NCI/ • Diagnostics for influenza virus SAIC). specific antibodies. Patent Status: PCT Application No. Advantages PCT/US09/42355 filed 30 Apr 2009, • Novel vaccine candidates. which published as WO 2009/135031 • Rapid production time. on 05 Nov 2009 (HHS Reference No. E– Development Status: In vitro and in 123–2008/0–PCT–02). vivo data can be provided upon request. Licensing Status: Available for licensing. Market Licensing Contact: Kevin W. Chang, • Vaccines. PhD; 301–435–5018; • Diagnostics. changke@mail.nih.gov. Inventors: Hana Golding and Surender Collaborative Research Opportunity: Khurana (FDA). The National Cancer Institute Biological Publications: Manuscripts are Research Branch is seeking statements available for review under a of capability or interest from parties Confidential Disclosure Agreement. interested in collaborative research to further develop, evaluate, or Patent Status commercialize the topic of this • U.S. Provisional Patent Application technology. Please contact John D. No. 61/257,785 filed 03 Nov 2009 (HHS Hewes, PhD at 301–435–3121 or Reference No. E–032–2010/0–US–01). hewesj@mail.nih.gov for more • U.S. Provisional Patent Application information. No. 61/325,216 filed 16 Apr 2010 (HHS Dated: July 2, 2010. Reference No. E–032–2010/1–US–01). Richard U. Rodriguez, Licensing Status: Available for Director, Division of Technology Development licensing. and Transfer, Office of Technology Transfer, Licensing Contact: Kevin W. Chang, National Institutes of Health. PhD; 301–435–5018; [FR Doc. 2010–16801 Filed 7–8–10; 8:45 am] changke@mail.nih.gov. and induce strong neutralizing antibody titers in several in vivo animal models. The key advantages of this technology are that expression of these proteins in bacteria reduces the vaccine production time and offers the ease of scalability for global usage, an issue with current production methods. The recombinant HA proteins can also be used for diagnostic applications. BILLING CODE 4140–01–P Substituted IL–15 Description of Invention: Interleukin– 15 (IL–15) is an immune system modulating protein (cytokine) that stimulates the proliferation and differentiation of T-lymphocytes. In the clinical context, IL–15 is being investigated for use in the treatment of diseases such as cancer. In vitro manufacture of IL–15 can be problematic. The invention relates to substituted IL–15 amino acid sequences of one or more amino acids that are predicted to reduce or eliminate deamidation of a specific aspargine amino acid residue found within the IL–15 protein. Deamidation can lead to protein degradation and interfere with the pharmaceutical purification and processing of IL–15. The invention also provides potential substituted gene sequences that encode the substituted IL–15 amino acid sequences. The PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which E:\FR\FM\09JYN1.SGM 09JYN1 Federal Register / Vol. 75, No. 131 / Friday, July 9, 2010 / Notices would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Integrative Cancer Biology in the Tumor Microenvironment (U01). Date: July 22, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Sherwood Githens, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8146, Bethesda, MD 20892, 301–435–1822, githenss@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science. Date: October 21, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select) 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Donald L. Coppock, PhD, Scientific Review Officer, Scientific Review and Logistic Branch, Division of Extramural Activities, NCI, National Institutes of Health, 6116 Executive Blvd., Rm 7151, Bethesda, MD 20892, 301–451–9385, donald.coppock@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 1, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–16803 Filed 7–8–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and VerDate Mar<15>2010 15:17 Jul 08, 2010 Jkt 220001 the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel. Date: November 4, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda, Maryland, Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814. Contact Person: Ruth Grossman, DDS, Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Room 960, Bethesda, MD 20892, 301–496–8775, grossmanrs@mail.nih.gov. Dated: July 1, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–16809 Filed 7–8–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; Review U01 Revision. Date: July 15, 2010. Time: 11 a.m. to 12:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Jayalakshmi Raman, PhD, Scientific Review Officer, Scientific Review Branch, National Institute of Dental and PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 39547 Craniofacial Research, One Democracy Plaza, Room 670, Bethesda, MD 20892–4878, 301– 594–2904, ramanj@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the intramural research review cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: July 1, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–16813 Filed 7–8–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Advisory Committee on Organ Transplantation; Notice of Meeting In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting: Name: Advisory Committee on Organ Transplantation. Date and Times: August 19, 2010, 8:30 a.m. to 4:45 p.m.; August 20, 2010, 8:30 a.m. to 3:30 p.m. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, Maryland 20814. Status: The meeting will be open to the public. Purpose: Under the authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, and 42 CFR 121.12 (2000), Advisory Committee on Organ Transplantation (ACOT) was established to assist the Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, and, thereby, increasing public confidence in the integrity and effectiveness of the transplantation system. ACOT is composed of up to 25 members, including the Chair. Members are serving as Special Government Employees and have diverse backgrounds in fields such as organ donation, health care public policy, transplantation medicine and surgery, critical care medicine and other medical specialties involved in the identification and referral of donors, non-physician transplant professions, nursing, epidemiology, immunology, law and bioethics, behavioral sciences, economics and statistics, as well as representatives of transplant candidates, transplant recipients, organ donors, and family members. Agenda: The morning of August 19, 2010, (8:30 a.m. to 11:30 a.m.) will be devoted to an orientation session for new members. The E:\FR\FM\09JYN1.SGM 09JYN1

Agencies

[Federal Register Volume 75, Number 131 (Friday, July 9, 2010)]
[Notices]
[Pages 39546-39547]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-16803]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which

[[Page 39547]]

would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Integrative Cancer Biology in the Tumor Microenvironment 
(U01).
    Date: July 22, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel, 5701 Marinelli Road, North 
Bethesda, MD 20852.
    Contact Person: Sherwood Githens, PhD, Scientific Review 
Officer, Special Review and Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Blvd., Room 
8146, Bethesda, MD 20892, 301-435-1822, githenss@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Innovative and Early Stage Development of Emerging 
Technologies in Biospecimen Science.
    Date: October 21, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select) 
8120 Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Donald L. Coppock, PhD, Scientific Review 
Officer, Scientific Review and Logistic Branch, Division of 
Extramural Activities, NCI, National Institutes of Health, 6116 
Executive Blvd., Rm 7151, Bethesda, MD 20892, 301-451-9385, 
donald.coppock@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: July 1, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-16803 Filed 7-8-10; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.